ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor
(Madrid:ORY.MC),(Boerse Stuttgart – Freiverkehr: ORN), MADRID, Spain and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, is pleased to announce the appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor. […]